Willingness to delay treatment during the COVID-19 surge
The majority of respondents were willing to delay their normal treatment timeline by 2 weeks or 4 weeks for early tumor stage oral cavity cancer (53.7%), while few were willing to delay 6 weeks (10.4%) and no respondents were willing to delay beyond 6 weeks (Figure 2). Respondents were least likely to delay treatment for a locally advanced oral cavity cancer as compared to other tumors that were assessed. For early stage glottic cancers and HPV-mediated oropharynx cancers, the largest percentage of surgeons were willing to wait up to 4 weeks with a minority of respondents willing to wait up to 8 weeks. Participants responded similarly in regards to locally advanced laryngeal cancers and recurrent laryngeal cancers with the largest group willing to wait up to 4 weeks for surgical therapy.